Laurus Labs reports Q2 & H1 FY27 results; signs deal for 60% stake in Galenvs Sciences
Laurus Labs Ltd · Pharmaceuticals & Biotechnology
What the filing says
- Q2 FY27 revenue ₹2,206 Cr (+33% y-o-y), EBITDA ₹762 Cr (+78%), gross margin 63.0%
- H1 FY27 revenue ₹4,233 Cr (+31% y-o-y), EBITDA ₹1,406 Cr (+72%), EBITDA margin 33.2%
- Galenvs: term sheet signed Oct 29, 2026 for 60% equity at pre-money USD 3.50 million, subject to due diligence
Why it's rated major development: the year-on-year change is 126% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Supreme Infrastructure India Ltd: NCLT grants extension for Scheme of Compromise
- RNFI receives RBI no-objection for acquisition of Smart Payment Solutions Pvt Ltd
- Pradeep Metals Limited files NCLT approval of Scheme of Amalgamation with Nami Capital Pvt Ltd
- Restaurant Brands Asia approves Sept 2026 results; PT Sari Burger OCPS investment
- Ashiana Housing signs JDA for Senior Living project in Sector 78, Gurugram
- IRB InvIT Fund acquires Solapur Yedeshi and CG Tollway from IRB Infrastructure Trust
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.